These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 27214859)

  • 1. Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical procedures.
    Shapiro AD; White Ii GC; Kim HC; Lusher JM; Bergman GE
    Haemophilia; 1997 Oct; 3(4):247-53. PubMed ID: 27214859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of immune response to mouse IgG in previously untreated haemophilia A and haemophilia B patients treated with monoclonal antibody purified factor VIII and factor IX preparations.
    Davis HM; Nash DW; Clymer MD; Frigo ML; Bergman GE
    Haemophilia; 1997 Apr; 3(2):102-7. PubMed ID: 27214718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine® SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis.
    Quon DV; Logan L
    Haemophilia; 2011 Jan; 17(1):e196-201. PubMed ID: 20618876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with a highly purified factor IX concentrate in patients undergoing surgical operations.
    Thomas DP; Lee CA; Colvin BT; Dasani H; Dolan G; Giangrande PL; Jones P; Lucas G; Cantwell O; Harman CT
    Haemophilia; 1995 Jan; 1(1):17-23. PubMed ID: 27214217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
    Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates.
    Kim HC; McMillan CW; White GC; Bergman GE; Horton MW; Saidi P
    Blood; 1992 Feb; 79(3):568-75. PubMed ID: 1531035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
    Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
    Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Cabrera N; Aznar JA; Woodward MK; Páez A
    Haemophilia; 2011 Jul; 17(4):590-6. PubMed ID: 21299747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañes M; Paez A
    Haemophilia; 2010 Mar; 16(2):240-6. PubMed ID: 20015218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study Group.
    Warrier I; Kasper CK; White GC; Shapiro AD; Bergman GE
    Am J Hematol; 1995 May; 49(1):92-4. PubMed ID: 7741147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies.
    Mauser-Bunschoten EP; Kleine Budde I; Lopaciuk S; Koopman MM; Van Der Meer FJ; Novàkovà IR; Ypma P; Van Der Linden PW; Windyga J; Strengers PF
    Haemophilia; 2011 May; 17(3):439-45. PubMed ID: 21362109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery.
    Schulman S; Wallensten R; White B; Smith OP
    Haemophilia; 1999 Mar; 5(2):96-100. PubMed ID: 10215956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B.
    Djulbegovic B; Marasa M; Pesto A; Kushner GM; Hadley T; Joseph G; Goldsmith G
    Am J Hematol; 1996 Feb; 51(2):168-70. PubMed ID: 8579061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single centre, real-world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery.
    O'Donovan M; Singleton E; Roche S; McGowan M; Benson J; Bergin C; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; Dougall A; O'Donnell JS; O'Connell NM
    Haemophilia; 2021 Nov; 27(6):e690-e697. PubMed ID: 34614282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
    Serban M; Skotnicki AB; Colovic M; Jinca C; Klukowska A; Laguna P; Wolf DM
    Haemophilia; 2012 Mar; 18(2):175-81. PubMed ID: 21812863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
    Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
    Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do patients with haemophilia undergoing cardiac surgery have good surgical outcomes?
    Rossi M; Jayaram R; Sayeed R
    Interact Cardiovasc Thorac Surg; 2011 Sep; 13(3):320-31. PubMed ID: 21712351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
    Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.